CUBEBIO attended ‘CancerX
Inaugural Member Summit 2023’, hosted in HHS(Health and Human Services) Mary E.
Switzer Building, Washington D.C. on 7th of September. CancerX is a
public-private partnership(PPP) appointed by the White House in attempt to
accelerate CANCER MOONSHOT, the US Government initiative against cancer.
Approximately 150 persons from more than 100 global businesses and the US
Government Departments including ARPA-H(Advanced Research Projects Agency for
Health) and the OASH (Office of the Assistant Secretary for Health) gathered to
discuss business management and measures to reduce cancer mortality. (Picture
Expecting quantum leap following a series of favorable news, Ltd., a
biomedical company specialized in the R&D and manufacture of IVD medical
devices, attracted $46.7Mn investment. The $24.1Mn primal deposit was paid on 21st
CUBEBIO is reviewing
a $98 million-worth investment and NASDAQ listing with an US corporation.
The key factor of
such large-scale investment is considered to be the successful clinical trial
results on urine-based pancreatic cancer diagnosis conducted in joint research
with SNUH(Seoul National University Bundang Hospital).
Signing the joint
technology development contract with SNUH last year, CUBEBIO proceeded pancreatic
cancer as its primary research target among various screen-able cancer types
using their technology. Pancreatic cancer is notorious for its extremely low
5-year survival rate of 13.9%. Despite the fact the only way to increase its
survival rate is through early detection, the rate of early diagnosis in
pancreatic cancer does not exceed 10%. The joint research team revealed that
biomarkers in urine can screen pancreatic cancer at an early stage with high
accuracy, which the related industries noted.
On 4th of August,
CUBEBIO signed to participate CANCER MOONSHOT, Biden Cabinet’s nation-wide
initiative against cancer, in recognition of its advanced technology. The core
of CANCER MOONSHOT is to introduce the recent technology in cancer diagnosis
and treatment and to politically and financially support the related parties in
an effort to reduce Americans’ death rate from cancer by 50% over the next 25
years. The US government is actively promoting the CANCER MOONSHOT, to the
extent that President Biden has formed a separate cabinet (Cancer Cabinet).
Cancer Moonshot is led by CancerX, a public-private partnership established by
the U.S. government, and major members include Johnson & Johnson,
AstraZeneca, Takeda Pharmaceutical, MD Anderson Cancer Center, Intel, and
Amazon Web Services.
On August 18th, an online meetup of CancerX members from many different
countries including CUBEBIO was held. During the conference, plans for future
operations such as reinforcing cooperation among cancer-related businesses were
discussed along with the introduction of the first steering committee
which consists of 12 global companies and institutions. On the 7th of this
month, about 150 attendees participated in the ‘CancerX Inaugural Member Summit
2023’, which consists of hundreds of global agencies and businesses including
CUBEBIO, at the HHS Mary E. Switzer Building, Washington D.C. with multiple US
Government Department personnel. During the ‘CancerX Inaugural Member Summit
2023’, CUBEBIO is said to have spotlighted the significance of early cancer
screening, drawing attention and support to the subject. Furthermore, the
company had conversed with major cancer center authorities in the US, such as
Memorial Sloan Kettering Cancer Center, City of Hope, and Moffitt Cancer
Center, about introducing the urine-based cancer screening system to the US.
Cooperation schemes were reviewed in regards to investment and US market debut
with the related parties from Yosemite founded by Reed Jobs, son of Steve Jobs
who died of pancreatic cancer, in attempt to invest in healthcare companies
targeting cancer and Medical & IT specialized investor, Andreessen
Horowitz, and more.
CUBEBIO, it anticipates collaborating with global companies and professional
institutions in the US and it has already begun discussing matters of
investment, sales, manufacturing, and production with US corporations including
CancerX members. The recent consensus to open ‘Cancer policy dialogue’ among
the trilateral leaders (KOR, US, JPN) reflects the US Government’s elevated
interest in the cancer industry. CUBEBIO entering the US market seems imminent
regarding its partnerships with global corporations in addition to such
In addition to the
Greater China market where the company is cooperating with the Hong Kong conglomerate,
CUBEBIO is conducting joint research with domestic institutions in Japan,
Singapore, and the Middle East. By overcoming the initial high entry barrier in
collaboration with the local institutions, such business model is expected to
promise a solid business structure within the domestic market. The foreign
institutions such as the National Cancer Centre Singapore are conducting joint
research with CUBEBIO. They anticipate CUBEBIO’s urine-based cancer screening
to play a notable role in their local field of early detection and diagnosis of
cancer. CUBEBIO is escalating to stably approach the MEDCs’ market via such
collaboration with multiple overseas agencies.
Meanwhile, in May
2023, CUBEBIO’s product was selected as an innovative product for the Scouter
Demo Day hosted by the PPS (Public Procurement Service), a government agency of
South Korea. The product will officially be listed as ‘PPS selected innovative
product’ and the agency will bind a public agency sales contract using $38
CUBEBIO is a
venture company whose product screens the presence of cancer by analyzing
biomarkers within urine.
The company holds
34 patents including the biosensor patent shared by Samsung Electronics. Two
more patents are settled to be issued as a result of its consistent R&D.
The company’s technology can be specified as ▲Convenient method of examination,
▲Frequent screening via non-invasive specimen, urine, ▲Screening multiple types
of cancer in 1 test, and ▲Deriving results within 5 minutes.
Korea JoongAng Daily: https://www.joongang.co.kr/article/25194332
Seoul Shinmun: https://www.seoul.co.kr/news/newsView.php?id=20230921500172&wlog_tag3=naver
Chosun Biz: https://biz.chosun.com/science-chosun/bio/2023/09/21/24POEL7WRZE67ESEOCP4TCNBYA/?utm_source=naver&utm_medium=original&utm_campaign=biz
Segye Times: https://www.segye.com/newsView/20230423500364
Medical Today: https://mdtoday.co.kr/news/view/1065602402955573